Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

Inclusion Criteria: * Histological proof of non-small cell lung cancer meeting one of the following criteria: * stage III b with a pleural effusion * stage IV * Histology must not be squamous cell. * No prior chemotherapy or hormonal therapy. * Prior radiation therapy must be completed at least 21 days prior to being registered for protocol therapy. * No prior use of an epidermal growth factor receptor (EGFR) inhibitor or antiangiogenic agent. * No treatment with any investigational agent within 30 days prior to being registered for protocol therapy. * Measurable disease according to RECIST and obtained by imaging within 28 days prior to being registered for protocol therapy. * ECOG Performance Status of 2 in the opinion of the treating investigator. * Age \> 18 years at the time of consent. * Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) while on treatment and for a 6 week period thereafter. * Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy. Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. * Females must not be breastfeeding. * Able to comply with study and/or follow-up procedures. Exclusion Criteria: * Evidence of bleeding diathesis or coagulopathy. * Evidence of central nervous system involvement or brain metastases confirmed by head CT or brain MRI within 28 days prior to being registered for protocol therapy. * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration for protocol therapy. * Anticipation of need for major surgical procedure during the course of the study. * Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to registration for protocol therapy. * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to registration for protocol therapy. * Serious, non-healing wound, ulcer, or bone fracture. * History of hemoptysis. * Clinically significant infections as judged by the treating investigator. * Other active malignancy